KR20160022803A - 암 치료 - Google Patents

암 치료 Download PDF

Info

Publication number
KR20160022803A
KR20160022803A KR1020157028621A KR20157028621A KR20160022803A KR 20160022803 A KR20160022803 A KR 20160022803A KR 1020157028621 A KR1020157028621 A KR 1020157028621A KR 20157028621 A KR20157028621 A KR 20157028621A KR 20160022803 A KR20160022803 A KR 20160022803A
Authority
KR
South Korea
Prior art keywords
cancer
mycobacterium
tumor
mtor
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157028621A
Other languages
English (en)
Korean (ko)
Inventor
토르스텐 하게만
Original Assignee
이모듈런 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이모듈런 테라퓨틱스 리미티드 filed Critical 이모듈런 테라퓨틱스 리미티드
Publication of KR20160022803A publication Critical patent/KR20160022803A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
KR1020157028621A 2013-05-09 2014-05-09 암 치료 Withdrawn KR20160022803A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1308325.8 2013-05-09
GBGB1308325.8A GB201308325D0 (en) 2013-05-09 2013-05-09 Cancer Therapy
PCT/GB2014/051421 WO2014181121A1 (en) 2013-05-09 2014-05-09 Cancer therapy

Publications (1)

Publication Number Publication Date
KR20160022803A true KR20160022803A (ko) 2016-03-02

Family

ID=48672024

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157028621A Withdrawn KR20160022803A (ko) 2013-05-09 2014-05-09 암 치료

Country Status (18)

Country Link
US (1) US20160074494A1 (https=)
EP (1) EP2994148B8 (https=)
JP (1) JP2016520057A (https=)
KR (1) KR20160022803A (https=)
CN (1) CN105407901A (https=)
AU (1) AU2014264434A1 (https=)
BR (1) BR112015025719A2 (https=)
CA (1) CA2907841A1 (https=)
DK (1) DK2994148T3 (https=)
ES (1) ES2618050T3 (https=)
GB (1) GB201308325D0 (https=)
HU (1) HUE031783T2 (https=)
MX (1) MX2015014344A (https=)
PL (1) PL2994148T3 (https=)
RU (1) RU2015143106A (https=)
SG (1) SG11201507847UA (https=)
SI (1) SI2994148T1 (https=)
WO (1) WO2014181121A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
KR20180015269A (ko) * 2015-06-24 2018-02-12 이모듈런 테라퓨틱스 리미티드 암 치료에 사용하기 위한 체크포인트 저해제와 마이코박테리움 전체 세포
KR101832892B1 (ko) * 2015-08-24 2018-02-27 가톨릭대학교 산학협력단 면역억제제로 유발되는 미토콘드리아 질환 및 면역 질환의 예방 또는 치료를 위한 메트포민을 포함하는 조성물
GB201601248D0 (en) * 2016-01-22 2016-03-09 Immodulon Therapeutics Ltd Cancer therapy
GB201608806D0 (en) * 2016-05-19 2016-07-06 Immodulon Therapeutics Ltd Method
WO2018112360A1 (en) * 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating cancer
WO2018112364A1 (en) * 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating melanoma
WO2019075452A1 (en) * 2017-10-13 2019-04-18 Evelo Biosciences, Inc. IDENTIFICATION OF BACTERIA FOR CANCER THERAPY
CN109329204B (zh) * 2018-10-12 2021-02-12 中国医学科学院北京协和医院 胰腺癌动物模型的构建方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4281200A (en) 1999-04-23 2000-11-10 Qlt Inc. Immuno-adjuvant pdt treatment of metastatic tumors
US20020022032A1 (en) 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
WO2006109300A1 (en) 2005-04-14 2006-10-19 Hadasit Medical Research Services & Development Ltd. Pre-transplantation treatment of donor cells to control graft versus host disease (gvhd) in transplant recipients
WO2008110491A2 (en) * 2007-03-09 2008-09-18 University Of Basel Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
EP2085466A1 (en) * 2008-01-29 2009-08-05 AEterna Zentaris GmbH Non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages, process of manufacturing and uses thereof
AU2010270030B2 (en) * 2009-07-08 2015-12-24 Baltic Bio Ab 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
US8617520B2 (en) * 2012-02-15 2013-12-31 Immodulon Therapeutics Limited Cancer therapy

Also Published As

Publication number Publication date
EP2994148A1 (en) 2016-03-16
EP2994148B1 (en) 2017-02-01
JP2016520057A (ja) 2016-07-11
AU2014264434A1 (en) 2015-10-08
ES2618050T3 (es) 2017-06-20
WO2014181121A1 (en) 2014-11-13
CN105407901A (zh) 2016-03-16
EP2994148B8 (en) 2017-08-30
DK2994148T3 (en) 2017-03-13
BR112015025719A2 (pt) 2017-07-18
GB201308325D0 (en) 2013-06-19
RU2015143106A (ru) 2017-06-15
US20160074494A1 (en) 2016-03-17
MX2015014344A (es) 2016-06-21
PL2994148T3 (pl) 2017-07-31
SG11201507847UA (en) 2015-11-27
HUE031783T2 (en) 2017-07-28
SI2994148T1 (sl) 2017-07-31
CA2907841A1 (en) 2014-11-13

Similar Documents

Publication Publication Date Title
KR20160022803A (ko) 암 치료
Locy et al. Immunomodulation of the tumor microenvironment: turn foe into friend
KR101820393B1 (ko) 암 치료에 사용하기 위한 체크포인트 저해제와 마이코박테리움 전체 세포
Ribas et al. Combining cancer immunotherapy and targeted therapy
Lu et al. Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: a combination nanomedicine approach
CN108392633A (zh) Pcsk9抑制剂在恶性肿瘤免疫治疗中的应用
Wan et al. Microbiome crosstalk in immunotherapy and antiangiogenesis therapy
Yoshida et al. Enhancement of the anti-tumor effect of DNA vaccination using an ultrasound-responsive mannose-modified gene carrier in combination with doxorubicin-encapsulated PEGylated liposomes
Qi et al. Exosomes in the lung cancer microenvironment: biological functions and potential use as clinical biomarkers
Guo et al. Cooperative effect of Bifidobacteria lipoteichoic acid combined with 5-fluorouracil on hepatoma-22 cells growth and apoptosis
US8617520B2 (en) Cancer therapy
Skalickova et al. Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer
Le et al. Immunostimulatory cancer chemotherapy using local ingenol-3-angelate and synergy with immunotherapies
Wong et al. Biological approaches to therapy of pancreatic cancer
JP2023513569A (ja) がんの治療用の細菌組成物
EP2548555A1 (en) Proton pump inhibitors as immunomodulators
Tomita et al. Histamine regulates growth of malignant melanoma implants via H2 receptors in mice
Shurin et al. Cancer therapy and dendritic cell immunomodulation
Adedayo et al. Emerging new treatments for colon cancer
US20260000716A1 (en) Methods and compositions for the treatment of cancer
Stanger et al. KRAS Inhibitors in Pancreas Cancer: Facts and Hopes about the Immunotherapy We’ve All Been Waiting For
Liu Innovative local delivery of anticancer drugs in combination with an immunomodulatory tumor-targeting monoclonal antibody improves long-lasting antitumor effects in melanoma
Brito Cancer Immunotherapy: Current Landscape and Future Directions
Utoguchi et al. 44 Vaccination of dendritic cells pulsed with tumor endothelial cells inhibits tumor growth
Cantley 43 Targeting PI3K: where are we?

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151012

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid